ArticleCytotechnology2026
Licochalcone B inhibits oxidative stress and ferroptosis in diabetic nephropathy through regulating ATF3/SLC7A11/GPX4 axis.
Article in Cytotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is one of the most serious and common diabetes-associated complications. Licochalcone B is a chalcone that has been found to possess anti-diabetic activity. However, protective potential of licochalcone B in DN remains unclear. In this study, we investigated the protective effect of licochalcone B against DN both in vitro and in vivo. The results showed that licochalcone B protected HK-2 cells from high glucose (HG)-induced oxidative stress and ferroptosis. Further molecular docking and molecular dynamics simulation revealed the stable binding abilities of licochalcone B and activating transcription factor 3 (ATF3). We found that licochalcone B negatively regulated ATF3 expression. Licochalcone B also inhibited the HG-induced ATF3 expression in HK-2 cells. ATF3 overexpression reversed the inhibitory effects of licochalcone B on oxidative stress and ferroptosis in HG-induced HK-2 cells. Moreover, ATF3 overexpression downregulated the expression levels of solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4), which are two critical regulators of ferroptosis. In vivo assays also proved that licochalcone B administration significantly improved histopathological changes in kidney tissues from HFD/STZ mice. Overall, our findings suggested that licochalcone B exerted protective effect against DN through ameliorating oxidative stress and ferroptosis via regulating ATF3/SLC7A11/GPX4 axis. These results highlighted the therapeutic potential of licochalcone B in preventing and treating DN. Supplementary Information: The online version contains supplementary material available at 10.1007/s10616-026-00910-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.